ENDRA’s TAEUS Liver Device Delivers MRI-Level Consistency at Point of Care, Achieving 0.89 ICC in Clinical Study

Clinical Study Reveals TAEUS Liver’s High Reliability with 0.89 ICC

ENDRA Life Sciences’ (NASDAQ: NDRA) TAEUS® Liver device just reported eye-catching results: a clinical study showed an intraclass correlation coefficient (ICC) of 0.89, with a standard error of measurement (SEM) of just 3.3%. These numbers mark the device as highly consistent, rivaling the reliability of MRI—the gold standard—but at the patient’s bedside and at a fraction of the cost.

Consistent, Reproducible Results Outperform Traditional Ultrasound

The study involved 14 subjects, where independent operators performed repeated measurements on each individual. A total of 56 measurements were analyzed to evaluate not just consistency within the same user, but also reproducibility across different users—a vital requirement for any diagnostic tool intended for widespread clinical use. In both scenarios, the TAEUS device performed in the “Good to Excellent” range for diagnostic consistency. For comparison, traditional ultrasound techniques suffer from much higher operator-dependent variability, making TAEUS a potential upgrade for clinicians managing patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Key Study Results: Performance Metrics at a Glance

Addressing a Market for Over 2 Billion Patients

With nearly one-third of the global adult population suffering from some form of steatotic liver disease, the need for accurate, affordable, and repeatable diagnostic solutions is acute. MRI offers high precision but is expensive and not widely accessible. According to ENDRA, the TAEUS Liver device’s reliable results, even across different operators, positions it as a practical solution for routine screening and monitoring.

Potential Clinical Impact: Consistent Liver Fat Assessment Without MRI Costs

ENDRA’s technology could fill a major gap for clinicians and pharmaceutical companies monitoring responses to metabolic therapies. As new treatments for metabolic liver disease hit the market, being able to detect small yet meaningful changes in liver fat—without the burden of repeated MRI scans—could prove invaluable. The TAEUS system also holds promise for accelerating patient recruitment in clinical trials, as it can be more broadly deployed in primary care and resource-limited settings.

Takeaway: A Step Forward for MASLD Diagnosis and Management

The strong performance of ENDRA’s TAEUS device—ICC of 0.89 and SEM of 3.3%—shows that reliable, MRI-like liver fat measurement could soon be available at the point of care for millions of patients. If TAEUS continues to validate its consistency in larger and more diverse trials, it could transform the diagnostic landscape for metabolic liver disease.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI